Valuing care recipient and family caregiver time: A comparison of methods

International Journal of Technology Assessment in Health Care

Volumn 24, Issue 1, 2008, Pages 52-59

  Guerriere, Denise N ^a   Tranmer, Jennifer E ^b   Ungar, Wendy J ^a,c,d   Manoharan, Venika ^a   Coyte, Peter C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Hospital for Sick Children

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cystic fibrosis; Family caregiving; Time costs

Indexed keywords

ECONOMIC ANALYSIS; SENSITIVITY ANALYSIS; TIME MEASUREMENT; VALUE ENGINEERING;

CARE RECIPIENT TIME; CYSTIC FIBROSIS; FAMILY CAREGIVING; TIME COSTS;

HEALTH CARE;

ADULT; ARTICLE; CAREGIVER; CONTROLLED STUDY; CYSTIC FIBROSIS; FAMILY; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HOME CARE; HUMAN; INTERMETHOD COMPARISON; LEISURE; MAJOR CLINICAL STUDY; MALE; STATISTICAL SIGNIFICANCE;

ADULT; CAREGIVERS; COSTS AND COST ANALYSIS; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; ONTARIO; QUESTIONNAIRES; TIME FACTORS;

EID: 38549112925     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307080075     Document Type: Article

References (40)

1. Alcock D, Danbrook C, Walker D, Hunt C. Home care clients, providers and costs. Can J Public Health. 1998;89:297-300.
2. Bramwell E, Halpin D, Duncan-Skingle F, et al. Home treatment of patients with cystic fibrosis using the "Intermate": The first year's experience. J Adv Nurs. 1995;22:1063-1067.
3. Brouwer WB, Koopmanschap MA. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:563-569.
4. Browne GB, Arpin K, Corey P, et al. Individual correlates of health services utilization and the cost of poor adjustment to chronic illness. Med Care. 1990;28:43-58.
5. Canadian Cystic Fibrosis Foundation. Report of the Canadian patient data registry. Canadian Cystic Fibrosis Foundation; 2000.
6. Chan B, Coyte PC, Heick C. Economic impact of cardiovascular disease in Canada. Can J Cardiol. 1996;12:1000-1006.
7. Chappell NL, Havens B, Hollander MJ, et al. Comparative costs of home care and residential care. Gerontologist. 2004;44:389-400.
8. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Paediatr. 1997;131:809-814.
9. Coyte PC, Young W. Applied home care research. Int J Health Care Qual Assur Inc Leadersh Health Serv. 1997;10:i-iv.
10. Davis P, Drumm M, Konstan M. Cystic Fibrosis. Am J Respir Crit Care Med. 1996;154:1229-1256.
11. Di Matteo L, Di Matteo R. Public homecare expenditures in Canada. Can Public Policy. 2001;27:313-333.
12. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1995.
13. Economist. Annual earnings data. The Economist; 2001.
14. Government of Canada: Ottawa. News Release: 2000 EI premium reduction. Available at: www.hrdc-drhc.gc.ca. December 1, 2002.
15. Government of Canada: Ottawa. Schedule of Canada pension plan contribution rates. Available at: www.cpp-rpc.gc.ca. December 1, 2002.
16. Guerriere D, Ungar W, Corey M, et al. Evaluation of the ambulatory and home care record: Agreement between self reports and administrative data. Int J Technol Assess Health Care. 2005;22:203-210.
17. Guerriere D, Wong A, Croxford R, et al. Costs and determinants of privately-financed home-based health care in Ontario, Canada. Health Soc Care Community. In press.
18. Guerriere DN, Tullis E, Ungar WJ, et al. Economic burden of ambulatory and home-based care. Treat Respir Med. 2006;5:351-359.
19. Ireys HT, Anderson GF, Shaffer TJ, Neff JM. Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid program, fiscal year 1993. Pediatrics. 1997;100(pt 1):197-204.
20. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis in Alberta: A regression approach to determining important cost drivers. Alberta: Institute of Health Economics Working Paper, 99-2; 1999:1-22.
21. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: A regression approach to determining the impact of recombinant human DNase. Pharmacotherapy. 1999;19:1159-1166.
22. Koopmanschap MA, Van Ineveld BM. Towards a new approach for estimation indirect costs of disease. Soc Sci Med. 1992;34:1005-1010.
23. Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics. 2003;21:1001-1024.
24. LeLorier J, Perreault S, Birnbaum H, et al. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clin Ther. 2000;22:140-151.
25. Leong VW, Guerriere DN, Croxford R, Coyte P. The magnitude, share and determinants of private costs incurred by clients (and their caregivers) of in-home publicly financed care. Healthcare Policy. In press.
26. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics. 1999;103:e72.
27. McCance K, Huether S. Pathophysiology: The biological basis for disease in adults and children. Toronto: C.V. Mosby Company; 1991.
28. Nielsen R, Gyrd-Hansen D. Prenatal screening for cystic fibrosis: An economic analysis. Health Econ. 2002;11:285-299.
29. North York Community Care Access Centre, North York Community Care Access Centre.
30. Pauly M. In: Lloyd-Still J, ed. Textbook of cystic fibrosis. Boston: John Wright PSG Inc; 1983.
31. Rothermich EA, Pathak DS. Productivity-cost controversies in cost-effectiveness analysis: Review and research agenda. Clin Ther. 1999;21:255-267.
32. Shepperd S, Harwood D, Gray A, et al. Randomised controlled trial comparing hospital at home care with inpatient hospital care. II. Cost minimisation analysis. BMJ. 1998;316:1791-1796.
33. Stastistics Canada. Consumer price index, historical summary, by province or territory. Montreal: Statistics Canada; 2006.
34. Stommel M, Given C, Given B. The cost of cancer home care to families. Cancer. 1992;71:1867-1874.
35. Tullis D, Guyatt G. Quality of life in cystic fibrosis. Pharmacoeconomics 1995;8:23-33.
36. Van Den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care: An overview of methods and applications. Eur J Health Econ. 2004;5:36-45.
37. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
38. Wildhagen MF, Verheij JB, Verzijl JG, et al. The nonhospital costs of care of patients with CF in The Netherlands: Results of a questionnaire. Eur Respir J. 1996;9:2215-2219.
39. Wildhagen MF, Verheij JB, Verzijl JG, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1991. Thorax. 1996;51:298-301.
40. Yates B. Analyzing costs, procedures, processes and outcomes in human services. California: Sage Publications; 1997.